Amgen Rating Reiterated by TheStreet (AMGN)
Amgen (NASDAQ:AMGN)‘s stock had its “buy” rating reiterated by analysts at TheStreet in a research report issued to clients and investors on Monday, AnalystRatings.NET reports.
The analysts wrote, “Amgen (AMGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.”
A number of other firms have also recently commented on AMGN. Analysts at Argus raised their price target on shares of Amgen from $130.00 to $135.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Amgen in a research note to investors on Thursday. They now have a $125.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Amgen from $133.00 to $138.00 in a research note to investors on Wednesday, January 29th. Nine research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $124.22.
Amgen (NASDAQ:AMGN) opened at 120.07 on Monday. Amgen has a one year low of $82.92 and a one year high of $124.46. The stock has a 50-day moving average of $116.5 and a 200-day moving average of $112.9. The company has a market cap of $90.653 billion and a P/E ratio of 17.91.
Amgen (NASDAQ:AMGN) last released its earnings data on Tuesday, January 28th. The company reported $1.82 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.69 by $0.13. The company had revenue of $5.01 billion for the quarter, compared to the consensus estimate of $4.81 billion. During the same quarter last year, the company posted $1.40 earnings per share. Amgen’s revenue was up 13.1% compared to the same quarter last year. On average, analysts predict that Amgen will post $8.17 earnings per share for the current fiscal year.
Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.